Filing Flows › Comparisons › ORGO vs NUVB
Organogenesis Holdings vs Nuvation Bio: ORGO and NUVB compared
Organogenesis Holdings is the larger company: $45.5M of revenue in its latest quarter (Q3 2026) against $45.0M for Nuvation Bio (Q3 2026). Nuvation Bio is growing faster (+243% against -70% a year earlier). Organogenesis Holdings is more profitable, with an operating margin of -64.9% against -93.9%.
Where the money goes: ORGO and NUVB
Organogenesis Holdings (ORGO) · Q3 2026
Organogenesis Holdings, Q3 2026: revenue $45.5M (-70% year over year), operating margin -64.9%, net loss $29.6M, operating cash flow −$18.6M. The chart follows the revenue to costs, profit and cash.
Nuvation Bio (NUVB) · Q3 2026
Nuvation Bio, Q3 2026: revenue $45.0M (+243% year over year), operating margin -93.9%, net loss $41.9M, operating cash flow −$38.6M. The chart follows the revenue to costs, profit and cash.
| Organogenesis Holdings (ORGO) | Nuvation Bio (NUVB) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $45.5M | $45.0M |
| Revenue growth, Y/Y | -70% | +243% |
| Operating margin | -64.9% | -93.9% |
| Net earnings | −$29.6M | −$41.9M |
| Net margin | -65.2% | -93.2% |
| Operating cash flow | −$18.6M | −$38.6M |
| Market value | — | $1.5B |
| Analysts’ mean target | — | $13.00 |
Where the revenue comes from
Nuvation Bio
- Product Revenue: $27.5M (61%)
- License: $17.5M (39%)
Questions
Which is bigger, Organogenesis Holdings or Nuvation Bio?
Organogenesis Holdings is the larger company: $45.5M of revenue in its latest quarter (Q3 2026) against $45.0M for Nuvation Bio (Q3 2026).
Is Organogenesis Holdings or Nuvation Bio growing faster?
Nuvation Bio is growing faster (+243% against -70% a year earlier).
Which is more profitable, Organogenesis Holdings or Nuvation Bio?
Organogenesis Holdings is more profitable, with an operating margin of -64.9% against -93.9%.
More: Organogenesis Holdings earnings · how Organogenesis Holdings makes money · Nuvation Bio earnings · how Nuvation Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.